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Broadening substrate specificity of a
chain-extending ketosynthase through a single
active-site mutation†
Annabel C. Murphy,*a Hui Hong,a Steve Vance,ab R. William Broadhursta and
Peter F. Leadlay*a
An in vitro model system based on a ketosynthase domain of the
erythromycin polyketide synthase was used to probe the apparent
substrate tolerance of ketosynthase domains of the mycolactone
polyketide synthase. A specific residue change was identified that
led to an emphatic increase in turnover of a range of substrates.
Themanipulation of biosynthetic pathways provides a useful source
of novel analogues of pharmaceutically-important, complex natural
products,1 as well as cost-effective and sustainable routes to known
compounds.2–4 Modular type I polyketide biosynthesis in particular
provides an attractive platform for producing rationally engineered
biocatalysts that can generate organic molecules of specified shape
and size.5
In the biosynthesis of complex reduced polyketides, such as
mycolactone (1) and erythromycin A (2) (Fig. 1), by actinomycete
bacteria, carbon chains of specific length are produced from
small monomers on assembly-line modular polyketide synthase
(PKS) multienzymes, each successive module catalysing a different
cycle of chain extension.6,7 The key step of carbon–carbon bond
formation involves a thioester-templated Claisen condensation
reaction, catalyzed by a ketosynthase (KS), between the growing
chain tethered to the KS active site, and a chain-extendingmonomer
borne on an acyl carrier protein (ACP) domain. Selection and
loading of the chain-extending monomer is carried out by an
acyltransferase (AT) domain. The b-ketoacyl-ACP intermediate
resulting from condensation may undergo reduction before
transfer to the next module, the degree of reduction depending
on the presence of ketoreductase, dehydratase and enoyl
reductase enzymes in each respective module. Many examples
of domain or module replacement, insertion and deletion to give
functional chimæric PKSs have been described.8 Unfortunately
these hybrid modular PKSs are often much less efficient than the
parent native PKS. Early model studies showed that KSs have
some intrinsic tolerance for different substrates.9,10 However, the
inherent substrate specificity of the KS in the adjacent down-
stream module may often limit the activity of hybrid modular PKS
systems.11–13 The role of KS specificity in assembly-line polyketide
biosynthesis has been previously explored in trans-AT PKSs, which
lack in-built AT domains in each module. Bio-informatic analysis
of their KS sequences has shown that they form distinct clades
corresponding to the chemistry of their substrates.14 This
structure-selectivity correlation, which has been confirmed by
in vitro functional analysis,15–18 implies that native trans-AT KS
domains may be generally poor catalysts for extension of non-
natural chains. In contrast, the sequences of KS domains from
a given cis-AT PKS tend to form a single clade, irrespective of the
chemical nature of the substrate at each stage of elongation.14
Fig. 1 Chemical structures of mycolactone and erythromycin.
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Although apparently more promising as catalysts operating within
hybrid PKS assemblies, the determinants of KS active site speci-
ficity in cis-AT systems remain rather poorly understood.8 A better
understanding of individual structural features that determine
specificity would greatly assist the re-engineering of chimæric
systems to improve function.
A valuable framework for detailed analysis of KS specificity has
been provided by X-ray crystal structures determined for several
KS domains.16,19–22 Structure-based sequence alignment of both
cis-AT and trans-AT KS domains has revealed three variable
regions within KS domains; a ‘‘clasping loop’’, a ‘‘dimer inter-
face loop’’ and an ‘‘active site cap’’ (Fig. S1, ESI†).21 In an earlier
comparison of the erythromycin PKS (6-deoxyerythronolide B
synthase, DEBS) KS5AT5 and KS3AT3 structures,20 the difference
in conformation adopted by the dimer interface loop was similarly
suggested to contribute to the different substrate specificity of KS3
and KS5. Roles in determining substrate specificity in trans-AT KS
domains have been plausibly assigned to the amino acid residue
immediately N-terminal of the essential active site Cys,15,17,18 but
there have been no equivalent successes for the KS domains of
cis-AT PKSs. Also, at the outset of our work there was no evidence
that engineered sequence changes in cis-AT KSs might improve
tolerance for non-natural acyl-ACP substrates.
A new approach to this question is suggested by the existence
of a natural cis-AT PKS showing an exceptionally high level of
sequence identity (497%) between KS domains in different
extension modules, even though the KSs act on substrates that
vary significantly in chain length and chemical functionality.
This is the PKS responsible for generating mycolactone (1) in
Mycobacterium ulcerans, the causative agent of Buruli ulcer.23–25
This multienzyme appears to offer a unique natural example of
broad KS substrate tolerance. In principle, mycolactone mod-
ules might serve as universal building blocks in combinatorial
polyketide biosynthesis. Unfortunately, the slow-growing mycolac-
tone producer is intractable for genetic manipulation,26 and the
PKS is not active upon heterologous expression.27 Insertion of amyc
KS domain into a heterologous PKS assembly line to replace the
resident KS is not expected to be effective, due to deleterious effects
on KS:AT and KS:ACP protein:protein interfaces.
To learn from the remarkable tolerance of myc KS domains,
we instead analysed in silico the active site differences between
modelled mycolactone KS domains and the experimentally-
determined crystal structure of the DEBS KS3AT3 didomain
(EryKS3AT3).20 Guided by this comparison, we then replaced
specific amino acids in the EryKS3 active site by their mycolactone
KS counterparts, and determined the condensation activity of
each mutant KS3 enzyme towards a panel of surrogate thioester
substrates in vitro. We report here that although most of the
mutants conserved the catalytic properties of the parent enzyme,
the replacement of a specific alanine residue by tryptophan
markedly improved both catalytic turnover and the ability of
the enzyme to act on non-natural substrates, encouraging the
view that the performance of chimæric cis-AT PKS multienzymes
may be improved by active-site engineering.
In silico comparison between the KS domains of the mycolactone
PKS and the EryKS3AT3 crystal structure: an in silico model of
the KS domain from MlsA2 was generated using Phyre229 and
compared with the EryKS3AT3 didomain crystal structure,20
to identify amino acid residues likely to define the extended
substrate binding pocket of the KS domain. The catalytically
essential residues Cys202, His337 and His377 (EryKS3 domain
numbering) occupy the same positions as theirMlsA2 counterparts.
However, seven EryKS3 residues (Ala154, Lys155, Phe156, Val173,
Ala230, Phe263 and Phe265) are replaced by other amino acids
in MlsA2 KS (Fig. S2, ESI†). Except for Ala154 and Phe265, the
substitutions are the same in all 16 mycolactone KS domains
(Lys155Ala, Phe156Glu, Val173Met, Ala230Thr, and Phe263Thr).
Ala154 is replaced either by Gly or Trp, and Phe265 is either
conserved or replaced by Trp. These seven residues were therefore
selected for mutagenesis of the EryKS3 domain, to determine their
potential role in promoting broader substrate specificity.
To gain insight into specificity determinants in cis-AT KS
domains, we used a sequence alignment of 199 domains to
compute the sequence variability at a given position of a cis-AT
KS domain, expressed as the percentage of sequences where the
consensus residue is present (Fig. S3 and S8, ESI†). This showed
that for cis-AT KS domains the ‘‘dimer-interface loop’’ is the most
prominently variable. Residues Ala154, Lys155, Phe156 chosen
for mutagenesis in this study reside within this loop.
Mass spectrometric assay for in vitro ketosynthase activity: the
catalytic competence of recombinant EryKS3AT3 has previously
been monitored using a radio-TLC based assay involving radiola-
belled N-acetylcysteamine (NAC) thioester 15.30 More recent studies
on trans-AT KS domains have successfully used mass spectrometry
to assay both self-acylation of the KS15,16 and subsequent Claisen
condensation.17 We also chose a mass spectrometric method to
directly monitor the formation of ketide-ACP condensation
products, starting from an acyl-NAC thioester, recombinant
EryACP3 and either methylmalonyl- or malonyl-CoA. Acyl-NAC
thioesters are convenient surrogate substrates for EryKS3AT3
even though where Km values have been reported they are
2–3 orders of magnitude higher than those of the corresponding
acyl-ACP substrates.10 First, we confirmed that when diketide
NAC-thioester 15 was incubated with methylmalonyl-EryACP3 in
the presence of EryKS3AT3, as described in the ESI,† a new acyl-
EryACP3 species was formed whose mass corresponded to that of
the expected Claisen condensation product. A panel of acyl-NAC
thioesters was then synthesised (Fig. 2) and assayed as substrates
for Claisen condensation by KS3. This panel included acyl-
thioesters of varying chain length; acyl-thioesters containing each
of the functional groups routinely encountered during polyketide
biosynthesis (b-keto-, b-hydroxy- and 2-enoyl-thioesters); and
acyl-thioesters bearing an alkyl branch. For each substrate, the
percentage of ACP bearing the respective ketide condensation
product after 1 h of incubation was measured (Table 1). Acyl
transfer from SNAC thioesters to holo-EryACP3 was an observable
background reaction, but this was not accelerated by the presence
of EryKS3AT3, and is presumably the result of direct chemical
thioester–thiol exchange. Substrates featuring a,b-unsubstituted
thioesters were also susceptible to side reactions involving 1,4-
conjugate addition of phosphopantetheine. Of the substrates
tested, as well as the diketide thioester 15, the alkanoyl thioesters
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3 and 4, the C-2 branched thioesters 7 and 8, and the 2,3-
unsaturated thioester 10 yielded modest amounts (2–6%) of
b-ketoacyl-ACP species.
Different mycolactone KS domains efficiently carry out con-
densation with either malonyl- or methylmalonyl-ACP as extender
units25 so we also sought to evaluate the effect of the chosen
active site mutations on the ability of EryKS3AT3 to catalyze
condensation with malonyl-ACP. In fact, even native EryKS3AT3
has been reported to catalyse condensation with malonyl-ACP
as the extender unit in vitro, albeit less efficiently than with the
natural methylmalonyl-ACP substrate.30 The malonyl-CoA-specific
AT from MLS module 9 was cloned and expressed, and used to
prepare malonyl-ACP3 (see Fig. S7, ESI†) in situ from holo-EryACP3.
EryKS3AT3 and a NAC thioester substrate were added to initiate
condensation. Wild type KS3AT3 accepted the same NAC thioester
substrates and gave similar yields of condensation product from
both malonyl- and methylmalonyl-ACP (see Table S4, ESI†). These
results show that the KS3 does not discriminate between these two
ACP bound extender units, consistent with previous studies.31
The point mutation Ala154Trp dramatically improves in vitro
ketosynthase condensing activity against several substrates: having
established the reactivity of wild type EryKS3AT3 with this range
of NAC thioester substrates and with two alternative extender
units, the mutant EryKS3AT3 enzymes were tested using the
same conditions (Table 1 and Table S4, Fig. S5, ESI†). Most
mutations were found to exert little effect on either substrate
(SNAc or extender unit) specificity or the overall yield of the
reaction, with two notable exceptions. First, the condensation
activity was completely abolished in the EryKS3AT3 mutant
Phe265Trp, for all substrates tested, although its acyl transferase
activity remained intact (data not shown). The residue is located
(Fig. S2, ESI†) close in space to the catalytic triad required for
KS-catalyzed condensation, and although Trp is tolerated in
this position in certain mycolactone KS domains, it may be that
here the increased steric bulk of the tryptophan sidechain
interferes with either initial acylation of the KS or the condensa-
tion reaction itself. In contrast, mutant Ala154Trp showed a
markedly increased substrate tolerance, giving b-ketoacyl-ACP
product from nearly all SNAC thioesters tested, with the exception
of b-ketoacyl SNAC thioesters 18 and 19. This mutant also
showed a significant increase in turnover of substrates compared
to the wild type enzyme. To confirm these preliminary results,
side-by-side comparison of Ala154Trp with the wild type was
repeated with the inclusion of an internal standard to confirm
the stability of the ACP-bound Claisen condensation products.18
Side reactions proved to be less problematic in these experiments
and improved turnover was observed for both wild type and
mutant EryKS3AT3. However, Ala154Trp continued to be both
significantly more promiscuous and a more effective catalyst.
Detectable levels of condensation product could be observed for
substrate 5 even for the wild type, but only the mutant gave
condensation products from substrates 6, 9 and 11–14 (examples
shown in Fig. S5, ESI†). Comparative time courses for the wild
type and mutant were carried out using substrate 4, and initial
rates were extracted by fitting the data to an equation that allows
derivation of initial rates from reaction progress curves32 (Fig. S6,
ESI†). This confirmed that the initial rate with Ala154Trp is 4.5-fold
greater than with the wild type.
The Ala154Gly mutant behaved similarly to the wild type
enzyme, even though this substitution is found in certain myco-
lactone domains, so the observed effect is not simply related to
the size of the side-chain at this position. The observed increase
in both substrate tolerance and catalytic efficiency for Ala154Trp
suggests an important role for this region of the active site.
Fig. 2 Assay design and N-acetylcysteamine thioester substrates.
Table 1 Percentage of EryACP3 carrier protein bearing Claisen condensation
product after incubation with EryKS3AT3 or its mutants, methylmalonyl CoA
and synthetic SNAC substrate. T indicates that only trace levels were detected
(see ESI for details)
EryKS3AT3 A154G A154W K155A F156Q V173M A230T F263T F265W
3 4 4 46 3 T 6 4 T
4 3 6 83 6 7 4 2 23
5 77 T 3 T
6 13
7 1 5 20 2 T T T T
8 2 2 72 T 5 2 1 4
9 2
10 6 17 91 16 18 11 8 10
11 1 5
12 2
13 24
14 33
15 2 3 7 5 2 2 T 4
16
17 T T T
18
19
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Analysis of the EryKS3AT3 crystal structure using Pymol
(www.pymol.org) showed that at least local rearrangement of
the active site would be necessary to accommodate a Trp side-
chain in place of Ala154. This residue is located at the start of
the ‘‘dimer-interface loop’’,21 a region that shows a distinctive
lack of sequence conservation in cis-AT KS domains (Fig. S3,
ESI†), indicating a possible role in substrate selection. This
region is only partly structured in the crystal structure of
EryKS3AT3,20 and it may be that in the Ala154Trp mutant this
loop is significantly re-ordered. Not only does residue Ala154 lie
within the active site close to the dimer interface, but it is also
between two regions that cryo-EM studies have recently implicated
in docking interactions between the KS and both its ‘upstream’
and intramodular ACP28 (Fig. S1, ESI†). The exact mechanism by
which this mutation modulates KS specificity and KS:ACP binding
interactions remains to be defined by structural studies, which
are in progress. Meanwhile, this present finding mirrors an
analogous finding of improved substrate tolerance made for a
single active site residue substitution in an AT domain in the
erythromycin PKS.33 It provides important encouragement for
further exploration of targeted mutagenesis of residues predicted
to shape, or control access to, KS active sites, with a view to
expanding the range of acyl-ACPs accepted.
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